



## **RVL Pharmaceuticals plc to Present at Upcoming Conferences**

May 16, 2022

BRIDGEWATER, N.J., May 16, 2022 (GLOBE NEWSWIRE) -- RVL Pharmaceuticals plc (Nasdaq: RVLP) ("RVL" or the "Company"), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, will present at two upcoming conferences as follows:

### **H.C. Wainwright Global Investment Conference, Miami Beach, FL**

Date: Tuesday, May 24, 2022  
Time: 11:00 a.m. ET  
Webcast: [Click Here](#)

### **Jefferies Healthcare Conference, New York City, NY**

Date: Thursday, June 9, 2022  
Time: 1:30 p.m. ET  
Webcast: [Click Here](#)

The webcasts will be available thereafter via the Company's website [www.rvlpharma.com](http://www.rvlpharma.com) website under the "Investor & News" section.

### **About RVL Pharmaceuticals plc**

RVL Pharmaceuticals plc is a specialty pharmaceutical company focused on the commercialization of UPNEEQ® (oxymetazoline hydrochloride ophthalmic solution), 0.1%, for the treatment of acquired blepharoptosis, or low-lying eyelid, in adults. UPNEEQ is the first non-surgical treatment option approved by the FDA for acquired blepharoptosis.

### **Investor and Media Relations for RVL Pharmaceuticals plc**

Lisa M. Wilson  
In-Site Communications, Inc.  
T: 212-452-2793  
E: [lwilson@insitecony.com](mailto:lwilson@insitecony.com)